By George Ongkojoyo 
For decades, the field of oncology has operated under a general consensus regarding the role of the immune system in solid tumors: an abundance of regulatory T cells, or Tregs, typically signals a poor prognosis. These cells, which function as the natural "brakes" of the immune system to prevent autoimmune reactions, are frequently hijacked by tumors to create an immunosuppressive environment that shields malignant cells from the body’s natural defenses. However, colorectal cancer has long stood as a confounding anomaly in this paradigm. In many patients with colorectal malignancies, a high density of Treg cells is paradoxically associated with improved survival rates and better clinical outcomes.
A landmark study published in the journal Immunity by a multidisciplinary team at the Sloan Kettering Institute, the experimental research arm of Memorial Sloan Kettering Cancer Center (MSK), has finally provided a definitive biological explanation for this long-standing mystery. The research, led by senior authors Dr. Alexander Rudensky and Dr. Christina Leslie, reveals that Treg cells in colorectal cancer are not a monolithic population. Instead, they consist of two distinct subtypes with diametrically opposed functions—one that actively restrains tumor growth and another that fuels it. This discovery marks a significant shift in the understanding of tumor immunology and paves the way for more selective, effective immunotherapies for the majority of colorectal cancer patients.
The Paradox of the Colorectal Tumor Microenvironment
In most cancers, such as melanoma or lung cancer, Treg cells suppress the activity of "killer" CD8+ T cells, allowing the tumor to grow unchecked. Because of this, many experimental therapies have focused on depleting Treg cells entirely. However, when researchers applied these findings to colorectal cancer, the results were inconsistent. While some patients responded, others saw their disease progress more rapidly.
The MSK study focused on the most prevalent form of the disease: microsatellite stable (MSS) colorectal cancer with proficient mismatch repair (MMRp). This subtype accounts for approximately 80% to 85% of all cases. Unlike the rarer microsatellite instability-high (MSI-H) tumors, which are highly responsive to current checkpoint inhibitors like pembrolizumab (Keytruda), MSS tumors have historically been "cold"—meaning they do not respond well to immunotherapy.
The research team, led by first authors Dr. Xiao Huang, Dr. Dan Feng, and Dr. Sneha Mitra, utilized advanced mouse models and human patient data to dissect the immune landscape of these tumors. They discovered that the "beneficial" effect of Tregs observed in previous clinical data was driven by a specific subpopulation of cells that produce the signaling molecule interleukin-10 (IL-10).
A Tale of Two Subtypes: IL-10-Positive vs. IL-10-Negative Tregs
The central finding of the study is the identification of two functional classes of Treg cells within the colorectal tumor microenvironment. These cells are distinguished by their expression of IL-10 and their physical location relative to the tumor.
The Protective Subtype: IL-10-Positive Tregs
The researchers found that Treg cells expressing IL-10 play a crucial role in slowing tumor progression. These cells are primarily located in the healthy tissue surrounding the tumor or at the invasive margin. Their primary function is to suppress Th17 cells, a different type of immune cell that produces interleukin-17 (IL-17). In the context of the gut, IL-17 acts as a potent growth factor for cancer cells, promoting inflammation and tumor proliferation. By keeping Th17 cells in check, IL-10-positive Tregs indirectly limit the "fuel" available to the tumor. When the researchers experimentally removed these specific cells, the tumors in mouse models grew significantly faster.
The Harmful Subtype: IL-10-Negative Tregs
Conversely, the study identified a second population of Treg cells that do not produce IL-10. These cells are found deep within the tumor core and behave like the classic Tregs seen in other cancers. They focus their suppressive efforts on CD8+ T cells, the "soldiers" of the immune system capable of killing cancer cells directly. By silencing these defenders, IL-10-negative Tregs allow the tumor to thrive. The researchers observed that when this specific subtype was eliminated, the tumors shrank, and the immune system’s ability to attack the cancer was restored.
Decades of Foundation: The Rudensky Lab’s Contribution
This breakthrough is the culmination of more than 20 years of research by Dr. Alexander Rudensky, one of the primary architects of modern Treg biology. Dr. Rudensky’s earlier work was instrumental in identifying the Foxp3 transcription factor as the "master regulator" of Treg development. His career has been dedicated to understanding "immune tolerance"—the mechanism that prevents the body from attacking its own cells, beneficial gut microbes, and food antigens.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles," Dr. Rudensky stated. "This underscores the need for selective approaches. We cannot simply eliminate all Tregs; we must target the harmful ones while preserving the helpers."
The study also benefited from the computational expertise of Dr. Christina Leslie’s lab, which used single-cell genomic analysis to map the genetic signatures of these different cell populations. This high-resolution mapping allowed the team to confirm that the same two subtypes exist in human patients, not just in animal models.
Clinical Implications: Targeting CCR8 for Selective Depletion
The identification of these two subtypes provides a clear target for next-generation immunotherapy. The researchers discovered that the harmful, IL-10-negative Tregs express exceptionally high levels of a surface protein called CCR8. In contrast, the beneficial, IL-10-positive Tregs express much lower levels of this protein.
This distinction offers a "molecular handle" for drug development. By using monoclonal antibodies designed to target and deplete CCR8-expressing cells, clinicians may be able to selectively remove the cells that suppress the immune response without touching the cells that restrain tumor-promoting inflammation.
This approach is already moving into the clinical phase. Several pharmaceutical companies and academic institutions, including MSK, are currently conducting clinical trials to test CCR8-depleting antibodies. These trials are particularly focused on patients with MSS colorectal cancer who have failed to respond to standard-of-care treatments. The MSK study provides the strongest evidence yet that this strategy could transform the treatment landscape for a population that has long had few immunotherapy options.
Broader Impact: The "Barrier Tissue" Connection
The implications of this research extend beyond the colon. By analyzing large-scale datasets from 16 different types of cancer, the research team found that this "dual-Treg" pattern is also present in other "barrier tissues." These include the skin and the linings of the stomach, mouth, and throat.
These tissues share a common characteristic: they are constantly exposed to the external environment, including microbes and environmental toxins. In these locations, the immune system must maintain a delicate balance between fighting pathogens and preventing excessive inflammation that could damage the tissue. The researchers suggest that the IL-10-positive Treg population evolved to maintain this balance in barrier tissues, and its presence in tumors arising from these tissues is a remnant of that natural protective function.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them," explained Dr. Sneha Mitra. This suggests that the CCR8-targeting strategy could potentially be effective across a wide range of squamous cell carcinomas and other barrier-tissue cancers.
The Challenge of Metastatic Disease
While the study offers hope for primary tumors, it also revealed a critical shift in the immune environment when colorectal cancer spreads. When the researchers examined metastatic tumors in the liver—the most common site for colorectal cancer spread—they found that the beneficial IL-10-positive Tregs were largely absent.
In the liver, the harmful IL-10-negative Tregs dominated the landscape. In this specific context, the "paradox" of colorectal cancer disappeared, and the immune environment looked more like a typical solid tumor. Consequently, the researchers found that removing all Treg cells in the metastatic setting was actually beneficial for shrinking tumors. This finding highlights the complexity of cancer treatment and suggests that immunotherapy may need to be tailored not just to the type of cancer, but to the specific organ where the cancer is currently growing.
Future Outlook and Industry Response
The oncology community has reacted with cautious optimism to these findings. The ability to differentiate between "good" and "bad" immune cells within a single tumor represents a significant leap toward precision immunology. If the CCR8-depletion strategy proves successful in clinical trials, it could be combined with existing checkpoint inhibitors to turn "cold" MSS tumors into "hot" tumors that the immune system can recognize and destroy.
Funding for this extensive research was provided by several major institutions, including the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the Ludwig Center for Cancer Immunotherapy. Dr. Rudensky and his colleagues have already filed patents related to CCR8-based therapies, signaling a clear path toward commercial development and widespread clinical application.
As the medical community moves toward the next era of cancer treatment, the MSK study stands as a reminder that the immune system is a nuanced instrument. Understanding the fine-grained details of how immune cells interact with their environment is no longer just a matter of academic interest—it is the key to unlocking the next generation of life-saving therapies.